Skip to main content
Future Journal of Pharmaceutical Sciences
Download PDF

In-silico and in-vitro analysis of novel substituted benzimidazolyl derivatives for antimycobacterial potentials targeting enoyl acyl carrier protein reductase (InhA)

Future Journal of Pharmaceutical Sciences volume 8, Article number: 61 (2022) Cite this article

Abstract

Background

The emergence of mutated drug-resistant strains of Mycobacterium tuberculosis has reinvigorated the development of effective chemotherapy for MDR-TB (multidrug-resistant resistance tuberculosis). Enoyl acyl carrier protein reductase (InhA) involved in the mycobacterial fatty acid elongation system has been chosen as a potential target.

Result

All of the lead compounds had a definite Rf value and a sharp melting point, confirming that no tautomeric forms exist and that the keto (CO) group is apparent in the IR and 13C NMR spectrum data. Structure-based drug design revealed the presence of amino acid residues like TYR 158, ILE 194, and PHE 149 which are crucial for InhA inhibitory activity and were considered favorable interactions. Among all, compounds 4, 5a, and 5c showed better docking and binding free energy owing to favorable interactions. Interestingly, there was a strong correlation between the binding free energy and the antimycobacterial susceptibility assay, where compounds 4, 5a, and 5c had greater activity. All the lead compounds also had good oral absorption and gut permeability. The presence of a carboxylic linker (–COOH–) between benzimidazole and the rest of the structure of the lead compounds was found to be crucial for activity as the oxygen atom and hydroxyl group of the linker formed most of the favorable interactions. The presence of chlorophenyl showed a favorable effect on InhA inhibition which might be owing to its hydrophobic interaction with PHE 149.

Conclusion

Three of the seven lead compounds synthesized had an IC value of approximately 0.5 μg/ml in the in-vitro Alamar blue assay against the Mycobacterium tuberculosis H37Rv strain, which is roughly comparable to the standard marketed drug, Isoniazid (INH). This manifestation of promising activity that resulted from combining in-silico and wet lab experimentation could be a great starting point for developing potent antimycobacterial agents to combat multidrug-resistant tuberculosis.

Graphical abstract

Background

Tuberculosis (TB) is a contagious disease of global influence which poses a remarkable challenge due to the evolution of resistant strains of the airborne pathogen, Mycobacterium tuberculosis (Mtb). In the lungs, alveolar macrophages are the first to interact with the pathogen and can befoul all the other parts of the human body later [1]. The recrudescence of the disease is inevitable due to acquired resistance. According to the WHO, around 4 lakh new MDR-TB cases are resistant to Rifampicin. Ending the TB epidemic by 2030 is predominant among the health targets of WHO [2,3,4]. To circumvent the problems, novel target sites and newer chemotherapeutic agents need to be identified to combat issues associated with drug resistance.

Previous studies indicated the potential pharmacophoric unit responsible for antitubercular activity such as Benzimidazole [5,6,7], nitroimidazopyrazinone [8], carbamates [9], triazole [10], picolinohydrazonamides [11], thiazole [12], and pyrazolopyrimidine [13]. Among these, benzimidazole derivatives have shown a variety of biological activities such as antimycobacterial, antimicrobial, antihypertensive, anticoagulant, anti-inflammatory, antifungal, and anthelmintic [14]. Even marketed drugs such as albendazole (antimicrobial), omeprazole (antiulcer), and bendamustine (anticancer) are derivatives of benzimidazole. Drugs like aminobenzimidazole-1, SB-P3G2, and SB-P8B2 (II) are extensively used in preclinical studies as an antitubercular agents [7]. The antitubercular mechanism of benzimidazole is not known so far but is expected to have three different mechanisms. Firstly, because they are structural isosteres of purines, benzimidazoles have a bactericidal effect by preventing the formation of nucleic acids and proteins. Another mechanism is the inhibition of bacterial topoisomerases by benzimidazoles. Finally, the tubulin homolog filamentous temperature-sensitive Z polymerization can also be inhibited by benzimidazole [14].

INH is reported to be involved in the mycobacterial fatty acid elongation by its interaction with Fatty acid synthetase II (FAS II). INH targets and inhibits the NADH-dependent target InhA (Enoyl acyl carrier protein reductase). Moreover, the InhA inhibitors are also reported to block the biosynthesis of mycolic acids that form the mycobacterial envelope. During our study, INH was used as a standard drug.

Due to the activation of catalase-peroxidase (Kat G), INH forms a covalent adduct with NAD co-factor. It targets the mycobacterial cell wall in a forceful manner [15]. But, the frequent occurrence of mutation in Kat G (≥ 50%), inhA promoter (10–35%), and oxyR-ahpC region (10–40%) accounts for the INH resistance mechanism which is one of the major hurdles in treating MDR-TB [16]. Hence, the direct binding of compounds with InhA that do not require activation by the mycobacterial catalase-peroxidase (Kat G) is an important strategy for treating infections caused by INH-resistant strains. Hence, enoyl acyl carrier protein reductase (InhA) was chosen as the target for initial in-silico docking studies as well as the molecular dynamics study followed by in-vitro screening for Mtb. Consequently, benzimidazolyl hydrazide derivatives have been developed which may aid to overcome the resistance associated with the Kat G mutation.

The most prevalent tool in the Pharma industry used to ponder the structure and binding free energies in a stable ligand–protein complex with high specificity is structured-based drug designing. Ranking the drug-protein complexes to identify the correct binding pose is a rational approach to drug design [17]. The MM/GBSA study provides comprehensive information on the relative binding affinities of compounds in a database. Predicting ADME by QikProp furnishes the pharmacokinetic profile of the organic molecules. Molecular dynamic studies by DESMOND help to interpret the stability of the ligand–protein complex in a biological environment. This proposed in-silico and wet lab combinational study could help in generating new leads that combat the multidrug-resistant TB.

Methods

Hardware and software

The in-silico analysis was executed in the Maestro11 modeling package provided by Schrodinger, LLC, New York, NY, 2018–4, installed in Dell precision 7820, running on Centos7OS.

Chemical scheme preparation

During the study, a scheme of about forty benzimidazolyl amino and hydrazino molecules was created. ChemSketch (version 14.01, ACD/Labsrelease2012) was used to create the 2D structures. Each structure was drawn, and its IUPAC name was identified and saved in mol format. Figure 1 depicts the steps involved in the preparation of the scheme as well as the structure of the parent molecules where the substitution has been constructed. The detailed mechanism of product formation is given in the Additional file 1.

Fig. 1
figure 1

Steps involved in the scheme preparation and the structure of parent molecules where the substitution was made. AR = (4-chlorophenyl, 4-flurophenyl, 4-tolyl); AR’ = (4-carboxyphenyl, 2-hydroxy, 4-carboxy phenyl), AR’’ = (Nicotinoyl, phenyl, benzoyl). (i) Conc. Hcl at 100 ℃ for 30 min, (ii) 90% acetic acid at 75 ℃ for 45 min, (iii) C2H5OH for 3 h / add Conc. NH3 till product precipitation, (iv) C2H5OH / NaOH; stirred for 4 h; left overnight, (v) Glacial CH3COOH/H2O2; 3 h; kept overnight

Full size image

Synthesis and characterization of the top-ranked molecule obtained after structure-based drug design

The top-ranked ligand from the structure-based drug design was taken for the synthesis. Initially, an acetylation reaction between a secondary amine and acetyl chloride produces 1-acetyl-2-methyl-1H-benzimidazole (compound 1) [18]. It is followed by the Claisen-Schmidt reaction, whereby the condensation takes place at the –COCH3 group due to the electronegative nature of oxygen. The condensation reaction takes place in presence of aromatic aldehydes with a dropwise addition of concentrated sulphuric acid [19]. 1-[3-(4-substituted phenyl) acryloyl]-2-methyl-1H-benzimidazole (compound 2) from 1-acetyl-2-methyl-1H-benzimidazole intermediate on treatment with hydrogen peroxide in glacial acetic acid cyclizes to an oxiranyl carbonyl derivative [20]. The basic mechanism behind cyclization is cis-hydroxylation followed by dehydration. Finally, cleavage of the epoxy ring occurs on condensation with substituted aromatic amines and hydrazides in the presence of ethanol to form 4-[1-(4-substituted phenyl)-2-hydroxy-3-(2-methyl benzimidazol-1-yl)-3-oxo-propyl] substituted aromatic amino (compound 4) and hydrazide derivatives (compound 5a-f) [20, 21]. Chemicals were procured from Hi-Media Chem Ltd., Lancaster Ltd. Macleoids Pharmaceutical Ltd., Hayman Ltd., Fischer, S.D. Fine Chem Ltd., and Loba Chemie Pvt. Ltd. The compounds obtained were purified and dried using standard methods before use. Thin-layer chromatography was carried out using silica gel G plates, and Iodine vapors were used as the visualizing agent. UV spectra were recorded on JASCOV-530 UV/VIS spectrophotometer and IR spectra were recorded on Jasco FT/IR-410 at the Department of Pharmaceutical Analysis, PSG College of Pharmacy, Coimbatore. PMR spectra were recorded at IICT, Hyderabad & IISC, Bangalore. Mass spectra were recorded at JSS College of Pharmacy, Ooty. The elemental analysis was carried out at IICT, Hyderabad.

Structure-based drug design

Molecular docking, binding free energy calculations, ADME, and a molecular dynamic study were initially performed against the InhA enzyme using different modules of Maestro v11.4 to avoid unnecessary time consumption and chemical disposal in synthesizing all of the compounds. The crystal coordinate of InhA (PDB ID: 2NSD, Resolution: 1.90Å) was taken from the RCSB PDB (protein data bank). Protein was prepared by using the Protein Preparation Wizard which utilizes OPLS3 as a forcefield for energy minimization. Post-docking minimization was performed to improve the geometry of the generated poses. The Topmost poses were selected based on the Docking and binding free energy score. The PRIME MM/GBSA (Schrödinger, LLC, and New York-4) module was used to predict the binding free energy (ΔGbind) of the protein–ligand docked complexes. Several parameters related to absorption, distribution, metabolism, excretion, and toxicity are predicted by QikProp v5.4. Expensive experimental techniques, like HTS, can be avoided by accurately predicting the ADME properties beforehand to avoid testing compounds that won't work. For the molecular dynamic study, protein–ligand complexes were solvated in an orthorhombic box and entrenched in the three-site transferable intermolecular potential (TIP3P) water model. Overlapping water molecules were deleted and neutralized with Na+ ions. The system was relaxed using the OPLS3 force field. A constant temperature at 300 K was maintained and a 2.0 fs value was obtained in the integration step. The equilibrated system was simulated for a period of 50 ns using NPT ensemble class. Finally, the root mean square deviation (RMSD) was calculated to monitor the stability of the protein [22].

Biological evaluation

Alamar blue is an oxidation–reduction dye used for antimycobacterial screening [23]. Mtb H37Rv maintained in the Lowenstein-Jensen medium was used as the test organism [24]. All tests were carried out in duplicate. The final concentration of test compounds was such that the 200 μl of sample (100 μl of TB broth and 100 μl of bacterial suspension) contained 0.5, 1, 2.5, 5, 10, 25, 50 and 100 μg/ml of the test compound. INH was used as a standard for comparison. Well without the addition of compounds were used as blank and cells incubated with saline alone were considered as control [25]. All the cells were incubated at 37 °C. On the seventh day, 20 μl of Alamar blue solution was added to the first control well. The color changed from blue to pink, indicating sufficient growth. Therefore, the dye was added to all the wells and incubated for 6 h followed by fluorescence detection at an excitation and emission wavelength of 544 nm and 590 nm, respectively [26]. Alamar blue assay was carried out at Rajiv Gandhi Centre for Biotechnology, Trivandrum.

Statistical analysis

Data were expressed as Mean ± SD. Data analysis was done by one-way and two-way analysis of variance (ANOVA), followed by post hoc Tukey’s multiple comparison test. A probability value of less than 0.001 was considered as the statistical significance criterion. All the data followed the normal distribution curve and the variance of dependent variable was same for all the data. So, the significance of the data was measured using ANOVA. GraphPad Prism 9.0 was used to do all statistical calculations (GraphPad Software, Inc. La Jolla, CA, USA).

Result

Synthesis and characterization of lead compounds obtained from structure-based drug design

Synthesis of 4-[1-(4-substituted phenyl)-2-hydroxy-3-(2-methyl benzimidazol-1-yl)-3-oxo-propyl amino] substituted aromatic amino (compound 4) and hydrazide derivatives (compound 5a–f) [19,20,21,22].

1. Synthesis of o-phenylene diamine dihydrochloride: In 1 g of Conc. Hcl, 14 g of O-Phenylene Diamine were dissolved and heated (100 °C for 30 min) with 2 g of activated charcoal. The heated filtrate was then mixed with 50 ml of conc. HCl. Filtered and immediately cooled to 10 °C in a frozen ice combination. Afterward, it is rinsed with 5 ml of conc. HCl, and was vacuum-dried using a desiccator over NaOH.

2. Synthesis of 2-Methyl Benzimidazole: 4.38 g of the aforementioned intermediate was heated under reflux for 45 min with 20 ml of water and 5.48 g of 90% acetic acid and heated at 75 ℃. Drops of a concentrated ammonia solution were added as the mixture cooled and the product precipitated. Then recrystallization was carried out using 10% aqueous ethanol. TLC and the solvent system (benzene/methanol – 9:1) were used to confirm purity.

3. Synthesis of intermediate 1-acetyl-2-methyl-1H-benzimidazole (compound 1): Percentage yield: 58%. 2-methyl benzimidazole (1.33 g, 0.01 mol) was dissolved in 2 ml of ethanol placed in a three-necked flask, and (0.8 ml; 0.01 mol) of acetyl chloride was added and mixed thoroughly and left for 3–4 h. A concentrated ammonia solution was gradually added, and the precipitated product was collected and crystallized from aqueous ethanol (20%) [27]. The purity of the intermediate was checked by TLC (solvent system—benzene/methanol, 9:1).

4. Preparation of 1-[3-(4-substituted phenyl) acryloyl]-2-methyl-1H-benzimidazole (compound 2) from 1-acetyl-2-methyl-1H-benzimidazole (compound 1): Percentage yield: 62%. 1-acetyl-2-methyl-1H-benzimidazole (1.76 g; 0.01 mol) was dissolved in 2 ml of ethanol placed in a three-necked flask, and sodium hydroxide solution (30 ml; 10%) was added and the mixture was cooled. To this, different substituted aromatic aldehydes (0.01 mol) dissolved in 2 ml of ethanol were added, and the mixture was stirred for 4–5 h and was left overnight [21]. Concentrated Hydrochloric acid was added drop by drop till the solution was slightly acidic. The solid separated was filtered, washed with water, and dried. The crude product was crystallized from aqueous ethanol (50%) [28], and the purity was checked by TLC [Solvent system benzene/chloroform/methanol (60:20:20)].

5. Formation of intermediate 1-{[3-(4-substituted phenyl)oxiran-2yl]carbonyl}-2-methyl-1H-benzimidazole (compound 3): Percentage yield: 64%. The 1-{[3-(4-substituted phenyl)oxiran-2yl]carbonyl}-2-methyl-1H-benzimidazole from 1 –acetyl-2-methyl-1H-benzimidazole (2.98 g; 0.01 mol) was taken in a three-necked flask and dissolved in glacial acetic acid (50 ml) and hydrogen peroxide (6 ml; 0.01 mol), and this was stirred for about 3 h and left overnight. Crushed ice was added to the reaction mixture, and the product obtained was filtered and dried. The crude product was crystallized from aqueous ethanol (50%) [20, 21]. Purity was assessed by TLC [Solvent system benzene/chloroform/methanol (60:20:20)].

6. Synthesis of the final product, 4-[1-(4-substituted phenyl)-2-hydroxy-3-(2-methyl benzimidazol-1-yl)-3-oxo-propyl amino] substituted aromatic amino and hydrazide derivatives: Percentage yield: 65% (3a) and 68% (3b). Different substituted 1-[3-(4-substituted phenyl)oxiran-2yl] carbonyl derivative compounds (3.14 g; 0.01 mol) were taken in a round-bottomed flask and ethanol (50 ml) was added. Different substituted amines or hydrazides (0.01 mol) were added and refluxed at 70 ℃ for 24 h. When the reaction ended, the volume of the reaction mixture was concentrated to half and the mixture was poured on crushed ice [20, 21]. The solid that separated was crystallized and the purity was confirmed by TLC [Solvent system benzene/chloroform/methanol (60:20:20)].

Spectral elucidation of the novel synthesized lead compounds

Compound 4

Yield: 64%, (benzene/chloroform/methanol 60:20:20), Rf = 0.580; mp 204–206 °C. λmax 261 nm, IR (KBR, ν cm−1): 2935 (OH), 3255 (NH), 2819 (CH), 1600 (CO), 1355 (C=CAr 771 (CHAr bend). Analytical value calculated for C23H20N3O2Cl (405.00): C, 68.33; H, 4.95; N, 10.39. Found: C, 68.42; H, 4.91; N, 10.37. 1H NMR (DMSO –d6) δ (ppm):2.51 (3H, CH3); 4.0–4.2 (3H, CH, OH, NH); 4.7 (1H, CH); 7.4 (BenzimidazoleAr); 8.0 (9 H, Phenyl).13C NMR (DMSO –d6) δ (ppm):61 (C–Cl Ar); 83(C); 115–140 (CAr); 201(C=O). ADSLC-MS (m/z) calculated for C23H20N3O2Cl: 406 [m+1].

Compound 5a

Yield: 61%, (benzene/chloroform/methanol 60:20:20), Rf = 0.498; mp 203 °C. λmax 278 nm, IR (KBR, ν cm−1): 2988.9 (OH), 3058 (NH), 2843 (CH), 1687 (CO), 1587 (C=N), 1416 (C=C), 1178 (CN), 1093 (ClAr), 1011 (CH3). Analytical value calculated for C23H21N4O2Cl (420.89): C, 65.57; H, 4.98; N, 13.30. Found: C, 62.48; H, 4.93; N, 13.33. 1H NMR (DMSO –d6) δ (ppm): 2.1 (1H, NH); 2.5 (3H, CH3); 4.14–4.21 (2H, OH); 4.7 (2H, CH); 7.4–8.2 (13 H, aromatic). 13C NMR (DMSO –d6) δ (ppm):61 (CClphe); 81(C); 140 (C); 113–138 (CAr); 201 (C). ADSLC-MS (m/z) calculated for C23H21N4O2Cl:419.6 [m+1].

Compound 5b

Yield: 62%, (benzene/chloroform/methanol 60:20:20), Rf = 0.528; mp 175–177 °C. λmax 279 nm, IR (KBR, ν cm−1): 3453 (NH), 2729 (OH), 2811 (CH), 2350 (CO), 1594 (C=N), 1351 (C=C), 1089 (ClAr), 1002 (CH3). Analytical value calculated for C24H21N4O3Cl (448.90): C, 64.15; H, 4.67; N, 12.47. Found: C, 64.21; H, 4.72; N, 12.43. 1H NMR (DMSO –d6) δ (ppm): 2.0 (1H, NH); 2.51 (3H, CH3); 4.1–4.2 (2H, CH, OH); 4.7 (1H, CH); 7.6 (5 H, Ar), 8.1 (5H, Ph Ar). 13C NMR (DMSO –d6) δ (ppm):60 (CClPhen); 80 (C, C=O, CH); 141 (C, C=N); 115–140 (CAr); 168 (C, CONH); 201 (C, C=O). LC–MS (m/z) calculated for C24H21N4O3Cl: 448.90 [M + H]+. Found: 449.6[M−H]+.

Compound 5c

Yield: 64%, (benzene/chloroform/methanol 60:20:20), Rf = 0.462; mp 168–170 °C. IR (KBR, ν cm−1): 2992.98 (OH), 3054 (NH), 2839 (CH), 1684 (CO), 1592 (C=N), 1425 (C=C), 1176 (CN), 1093 (Cl Ar), 1019 (CH3). Analytical value calculated for C23H20N5O3 Cl (449.5): C, 61.46; H, 4.45; N, 15.59. Found: C, 61.57; H, 4.40; N, 15.62. 1H NMR (DMSO –d6) δ (ppm): 2.0 (1H, NH); 2.5 (3H, CH3); 4.0–4.3 (3H, CH, OH, NH); 7.3–7.5 (4 H, Ar); 8.0–8.2 (9H, Ar). 13C NMR (DMSO –d6) δ (ppm):60 (C, CH); 80(C, C=O, CH); 115–140 (CAr); 150 (C pyridyl); 167 (C, CONH); 200 (C, CO). LC–MS (m/z) calculated for C23H20N5O3 Cl: 449.5[M + H]+. Found: 448.1[M−H]+.

Compound 5d

Yield: 60%, (benzene/chloroform/methanol 60:20:20), Rf = 0.523; mp 176 °C. λmax 280 nm, IR (KBR, ν cm−1): 3444 (NH), 2811 (OH), 1685 (CO), 1594 (C=N), 1351 (C=C), 119.5 (FAr bend). 1H NMR (DMSO –d6) δ (ppm):2.0 (1H, NH); 2.5 (3H, CH3); 5.5 (1H, 4.0–4.3 (3H, NH, OH, CH); 6.8–7.8 (13 H, Ar). 13C NMR (DMSO –d6) δ (ppm): 83 (C); 140 (C); 114–139 (CAr); 16 (C, CONH); 201 (C). LC–MS (m/z) calculated for C24H21N4O3F: (432): [M + H]+. Found: 431[M−H]+.

Compound 5e

Yield: 58%, (benzene/chloroform/methanol 60:20:20), Rf = 0.568; mp 173–175 °C. λmax 274 nm, IR (KBR, ν cm−1): 3089 (NH), 2935 (OH), 2859.9 (CH), 2679 (CO), 1587 (C=N), 1342 (C=C), 1009 (CH3). 1H NMR (DMSO –d6) δ (ppm):2.51 (3H, CH3); 2.0 (1H, NH); 4.14–4.21 (2H, OH, CH); 8.1 (1H, NH); 7.2–7.6 (8 H, Ar).13C NMR (DMSO –d6) δ (ppm): 63 (C), 80 (C); 115–140 (CAr); 168 (CPh); 201 (C).

Compound 5f

Yield: 55%, (benzene/chloroform/methanol 60:20:20), Rf = 0.535; mp 174–176 °C. λmax 280 nm, IR (KBR, ν cm−1): 3482 (NH), 2929 (OH), 2811 (CH), 1594 (C=N), 1351 (C=C), 1039 (CH3). 1H NMR (DMSO –d6) δ (ppm): 2.51 (3H, CH3); 4.0–4.2 (3H, CH, OH, NH); 4.7 (1H, OH); 7.4–8.0 (13 H, aromatic). 13C NMR (DMSO –d6) δ (ppm):61 (C); 83 (C); 115–140 (CAr); 120–130 (CPh); 201 (C).

Molecular interaction of lead compounds with InhA

All molecules were docked against enoyl acyl carrier protein reductase (PDB ID: 2NSD). The docking score and binding free energy of all the benzimidazolyl amino and benzimidazolyl hydrazide derivatives are given in Tables 1 and 2, respectively. The top posed structure from the docking study was taken as lead compound (4, 5a, 5b, 5c, 5d, 5e & 5f) based on the docking and MM/GBSA binding free energy score. Among the lead compounds, Compound 4 was a benzimidazolyl amino derivative and the rest were benzimidazolyl hydrazides derivatives (5a-f). The molecular interaction between different amino acids and lead compounds along with INH is demonstrated in Fig. 2. The molecular interactions observed with each molecule are discussed below.

Table 1 Docking score and MM/GBSA ΔGbind score of lead benzimidazolyl amino derivatives
Full size table
Table 2 Docking score and MM/GBSA dG bind score of lead benzimidazolyl hydrazide derivatives
Full size table
Fig. 2
figure 2figure 2figure 2

Interaction of InhA with the seven best lead compounds generated using 2D-lignad interaction diagram of GLIDE module

Full size image

Compound 4 formed two hydrogen bond interactions and one Π-Π stacking. One hydrogen bond donor interaction was formed between ILE 194 and the hydroxyl group of the carboxylic linker and one hydrogen bond acceptor interaction was formed between LYS 165 and 3-amino of benzimidazole pharmacophore. A pi-pi stacking was made between chlorophenyl and PHE 149. All other lead compounds made a similar hydrogen bond interaction between the linker hydroxyl group and ILE 194 was observed. In compound 5e, the linker hydroxyl group made two hydrogen bond acceptor–donor interactions with ILE 194. Other than ILE 194, compounds 5b & 5f showed a hydrogen bond acceptor interaction between the oxygen atom of the terminal benzamide group and TYR 158. In the case of INH, hydrogen bond acceptor interaction was made between the oxygen atom of pyridine-4-carboxamide. During the study, all the lead compounds and INH showed similar amino acid interactions which were previously described as crucial for antitubercular activity (Table 3).

Table 3 Docking interactions of selected lead compounds
Full size table

ADME/tox prediction of lead compounds

ADME prediction was done for the parameters such as Lipinski’s rule of five, Jorgensen’s rule of three, CNS activity, HERG K + channel toxicity, Pcaco (nm/s), logBB, PMDCK (nm/s) & % Human oral absorption. Zero violation in RO5 and RO3 indicates that the molecules have a drug-like characteristic and can be orally available. The selected molecules showed lower CNS activity and lower permeability to the blood–brain barrier, which implies fewer CNS side effects. Permeability to the gut-blood barrier indicated by Pcaco was found to be excellent. The percentage of human oral absorption emphasizes an excellent oral absorption of the novel compounds, which also corresponds to good oral bioavailability (Table 4).

Table 4 Preliminary QikProp ADME predicted data for the seven best lead molecules
Full size table

Molecular dynamics study of lead compounds

A molecular dynamics study suggests that although not much conformational change was observed in the protein but for test molecules, conformational changes were more significant inside the binding pocket except for compound 5b. RMSD for all lead compounds was found to be stable at least after 35 ns was seen below 3 Å, which implies that the compounds formed a stable complex with InhA (Fig. 3). Interaction fraction analysis (molecular dynamics) showed that the majority of interaction was hydrophobic (Fig. 4). The majority of H-bond interaction that the lead compounds made was with TYR 158, ILE 194, and THR 196 (Fig. 5).

Fig. 3
figure 3

Protein–Ligand RMSD of lead compounds. Compound 4 = 3.2 & 5.2 Å, Compound 5a = 2.4 & 3.63 Å, Compound 5b = 3.2 & 4 Å; Compound 5c = 2.25 & 2.8 Å; Compound 5d = 2.4 & 4 Å; Compound 5e = 3.2 & 4 Å; Compound 5f = 3.2 & 3.6 Å

Full size image
Fig. 4
figure 4

Ligand–protein contact histogram of lead compounds. The green bar indicates H-bond interaction, the blue bar indicates water-mediated H-bond interaction and the violet bar indicates hydrophobic interaction between the ligand and the protein

Full size image
Fig. 5
figure 5figure 5figure 5figure 5

Ligand–protein contact of lead compounds. A diagram of the detailed interactions between the ligand atoms and the protein residues. In the chosen trajectory (0.00–50.05 nsec), interactions that occur more than 20.0% of the simulation period are displayed. As some residues may have many contacts of a single kind with the same ligand atom, it is feasible to have interactions with > 100%

Full size image

Biological screening

Antibacterial screening

The seven newly synthesized HIT compounds were screened for antibacterial activity against gram-positive Staphylococcus aureus and gram-negative Escherichia coli at a concentration of 250 μg/disk and 500 μg/disk. The results were compared with the standard drug Ciprofloxacin at 10 μg/ disk using DMSO as the vehicle [32, 33]. Novel compounds were inactive against gram-positive Staphylococcus aureus. Compounds 5a, 5b, and 5c exhibited mild activity at 500 μg/disk concentration, and 4, 5d, 5e, and 5f, showed moderate activity against Gram-negative Escherichia coli, at both 500 μg/disk and 250 μg/disk concentration.

Antimycobacterial susceptibility test using Alamar blue

The seven HIT molecules were evaluated for their antimycobacterial potentials using the Alamar blue assay model. Among the compounds screened for antitubercular activity using INH as standard, the compounds 5d & 5f showed an inhibitory concentration (IC50) of 5.38 and 5.13 μg/ml respectively. The compounds 5b & 5e had IC50 values of 1.02 and 0.95 μg/ml respectively. The compounds 4, 5a & 5c exhibited a highly significant inhibitory concentration of 0.51, 0.56 and 0.57 μg/ml which is equipotent to the standard marketed drug INH (IC50 = 0.52 μg/ml). A dose-dependent percentage reduction in Alamar blue (resazurin to resorufin) by all the test compounds was observed. With an increased dose, the percentage reduction of resazurin also declined. The amount of percentage reduction is directly proportional to the lower metabolically active cells and vice versa. There was no significant difference found when INH was compared to test compounds. There were high levels of percentage reduction in Alamar blue were observed in the control group when compared to INH and test compounds. Among all, compounds 4, 5a, and 5c treated well showed significant reduction (P < 0.001) in percentage reduction of Alamar blue by mycobacterium when compared to control. This shows significant inhibition of mycobacterium cell by compounds 4, 5a, and 5c. All the comparative data are given in Fig. 6.

Fig. 6
figure 6

Antimicrobial susceptibility test. The percentage reduction of Alamar blue (resazurin) to resorufin is a direct indication of mycobacterial viability. A lower percentage reduction of Alamar blue indicates greater mycobacterial susceptibility. The experiment was performed in a 96-well plate in duplicate. The data are expressed as Mean ± SD. The effective dose (LD50) of the compound 4, 5a, 5b, 5c, 5d, 5e, 5f and INH are 0.52, 0.56, 1.02, 0.57, 5.38, 0.95, 5.13, and 0.51 µg/ml respectively at which 50% of the mycobacterial cell death was observed. In case of control (saline), approximately > 90% of mycobacterial cells were viable. When compared to the control there was a significant percentage reduction of Alamar blue in all the groups, whereas when compared to INH there was no significant difference found. The superscript Z denotes statistical significance at p < 0.001. All statistical data were calculated using GraphPad Prism 5

Full size image

Discussion

The basic moiety, 2-methyl benzimidazole, has been reported to possess antitubercular activity [34, 35]. Benzimidazole moiety has been often used as a part of mycobacterial gyrase inhibitors as well as MtbFtsZ inhibitors, named after “filamenting temperature-sensitive mutant Z” [36]. This is the first protein to move to the division site during cell division and is essential for recruiting other proteins that produce a new cell wall between the dividing cells [37]. Considering the importance of benzimidazole moiety as an antimycobacterial principal segment, we have chosen the compounds with functionalized benzimidazole for the present in-silico and in-vitro analysis. Enoyl-acyl carrier protein reductase (InhA) is a prominent target of the current first-line drug INH, used in the treatment of tuberculosis infections [38, 39]. All our lead compounds showed a specific Rf value and a sharp melting point and therefore we confirm that there are no tautomeric forms present and the keto (CO) group appears to be visible in the IR and 13C NMR spectrum data.

In-silico analysis by docking, MM/GBSA ΔGbind, MD simulation, and ADME prediction resulted in bringing out novel seven HIT compounds having a good binding profile with the target, InhA. According to the ADME prediction by QIKPROP, the parameters selected were CNS, log HERG, PCaco (nm/s), logBB, PMDCK (nm/s), % Human oral absorption, Rule of five, and Rule of three. All the three compounds bear PCaco-2 values greater than 500 nm/sec which denotes good cell permeability. The blood–brain partition coefficient for oral drugs and the predicted CNS activity does not fall within the specified range and the above drugs are expected, not to enter the BBB. Hence the untoward CNS effects could be prevented. The HIT compounds satisfy Lipinski’s Rule of Five and Jorgensen’s rule of three without any violations. This is also an added fact that the compounds may have excellent oral absorption. Furthermore, values established from the parameter, % Human oral absorption, emphasize a very good oral absorption of the novel compounds which also corresponds to better oral bioavailability. As per the MM\GBSA ΔGbind prediction by PRIME, the above seven hits obtained from the docking study showed that test compounds have a good binding affinity toward the receptors. More negative the value, the better the binding affinity.

Further, an observation made by docking study showed TYR 158, ILE 194 and PHE 149 were critical during the InhA inhibition. Interestingly, all the seven compounds which were chosen for the synthesis demonstrated a similar kind of interaction along with standard INH. Also, the greater number of favorable interaction (TYR 158, ILE 194 and PHE 149) was observed in case of compound 5c, 5a, and 4. This observation improved the level of confidence during the study, and we proceeded with the synthesis of seven novel molecules.

In-vitro biological screening was carried out for the seven synthesized novel benzimidazolyl hydrazide and amino derivatives. The compounds 5d & 5f possess an inhibitory concentration of 5 μg/ml, Compound 5b & 5e have 1 μg/ml, and 4, 5a, and 5c exhibit an inhibitory concentration of 0.5 μg/ml as per the Alamar blue technique which is equivalent to that of the marketed standard drug INH. Interestingly, the in-vitro study was strongly correlated with the in-silico prediction, where by compound 4, 5a, and 5c showed greater number of favorable interactions. The chlorophenyl group seems to be an essential chemical segment in the novel molecule which contributes to the property of drug likeliness. The result from the in-vitro assay significantly correlated with the binding free energy prediction. This shows how crucial is drug designing in the process of drug discovery.

On account of the remarkable properties of Benzimidazoles, a series of derivatives with modifications have been virtually screened and synthesized to optimize their potency. By carrying out an in-vitro study (Alamar Blue assay), all the synthesized novel molecules were screened for antimycobacterial potentials against the strain, Mycobacterium tuberculosis H37 Rv strain using the standard INH. The compounds 4, 5a, and 5c displayed the most potent inhibitory activity possessing a MIC of 0.5 μg/ml which is equivalent to the standard drug INH. The presence of a carboxylic linker (–COOH–) between benzimidazole and the rest of the structure of the lead compounds was found to be crucial for activity as the oxygen atom and hydroxyl group of the linker formed most of the favorable interactions. The presence of the chlorophenyl group attached to the 3-oxo-propyl moiety in compound 4, 5a, and 5c dramatically enhances the antimycobacterial activity which is in line with the previous findings [6, 14]. This might be due to hydrophobic interaction with PHE 149 as presence of Cl in the para position of benzyl moiety is in close proximity of hydrophobic pocket in the target binding site [6]. When the chlorophenyl group in compounds 5e and 5f is replaced with a tolyl group, the MIC value changes to 1 g/ml and 5 g/ml, respectively. A similar pattern was also observed where replacing chlorine atom with methyl and cyano group in the para position of benzimidazole completely abolished the antimycobacterial activity [40]. Furthermore, 3-phenylamino, 3-phenylhydrazino, or 3-iso-nicotinyl hydrazino attachment to the third carbon atom of the oxo-propyl group had no significant effect on the antimycobacterial activity. Additionally, the presence of nitrogen in the amino, hydrazino, or iso-nicotinyl hydrazino group appears to be crucial for the activity. Thus, the addition of a substituted tolyl anilino group to 2-methyl benzimidazole has a significant impact on the product's ability to function as a lead compound. The use of benzimidazole instead of the isonicotinic acid hydrazide group helped to produce promising in-vitro antimycobacterial activity.

Conclusion

The present approach was made, having in mind the life-threatening nature of Tuberculosis as one of the thrust areas of drug research. The integrated analysis from the in-silico prediction and the wet lab experimentation may provide insights into designing novel antimycobacterial agents from a series of 2-substituted benzimidazolyl derivatives. This also proves that computer-aided molecular design techniques are fruitful in rational drug design. This could be a constructive attempt aimed to develop the next generation antitubercular InhA inhibitors for the treatment of multiple drug-resistant tuberculosis.

Limitation and future prospectives

The R and S configuration of the lead compounds was not included in the current study. Our future study plan will include R and S configuration as well as group projection priority.

Availability of data and materials

The data generated or analyzed during this study are included in this published article (and its Additional files).

Abbreviations

TB:

Tuberculosis

Mtb:

Mycobacterium tuberculosis

INH:

Isoniazid

FAS II:

Fatty acid synthetase II

InhA:

Enoyl acyl carrier protein reductase

Kat G:

Catalase-peroxidase

TIP3P:

Three-site transferable intermolecular potential

ΔG bind :

Binding free energy

RMSD:

Root mean square deviation

DMF:

Dimethylformamide

TLC:

Thin-layer chromatography

References

  1. Allard B, Panariti A, Martin JG (2018) Alveolar macrophages in the resolution of inflammation, tissue repair, and tolerance to infection. Front Immunol 9:1777. https://doi.org/10.3389/fimmu.2018.01777

    Article  CAS  Google Scholar 

  2. Vilchèze C, Wang F, Arai M, Hazbón MH, Colangeli R, Kremer L, Weisbrod TR, Alland D, Sacchettini JC, Jacobs WR (2006) Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 12:1027–1029. https://doi.org/10.1038/nm1466

    Article  CAS  Google Scholar 

  3. Lu XY, You QD, Chen YD (2010) Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis. MRMC 10:182–193. https://doi.org/10.2174/138955710791185064

    Article  CAS  Google Scholar 

  4. Sivakumaran D, Jenum S, Vaz M, Selvam S, Ottenhoff THM, Haks MC, Malherbe ST, Doherty TM, Ritz C, Grewal HMS (2020) Combining host-derived biomarkers with patient characteristics improves signature performance in predicting tuberculosis treatment outcomes. Commun Biol 3:359. https://doi.org/10.1038/s42003-020-1087-x

    Article  CAS  Google Scholar 

  5. Antoci V, Cucu D, Zbancioc G, Moldoveanu C, Mangalagiu V, Amariucai-Mantu D, Aricu A, Mangalagiu II (2020) Bis-(imidazole/benzimidazole)-pyridine derivatives: synthesis, structure and antimycobacterial activity. Future Med Chem 12:207–222. https://doi.org/10.4155/fmc-2019-0063

    Article  CAS  Google Scholar 

  6. Pieroni M, Tipparaju SK, Lun S, Song Y, Sturm AW, Bishai WR, Kozikowski AP (2011) Pyrido[1,2-a]benzimidazole-based agents active against tuberculosis (TB), multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB. ChemMedChem 6:334–342. https://doi.org/10.1002/cmdc.201000490

    Article  CAS  Google Scholar 

  7. Rückle T, Biamonte M, Grippi-Vallotton T, Arkinstall S, Cambet Y, Camps M, Chabert C, Church DJ, Halazy S, Jiang X, Martinou I, Nichols A, Sauer W, Gotteland J-P (2004) Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase. J Med Chem 47:6921–6934. https://doi.org/10.1021/jm031112e

    Article  CAS  Google Scholar 

  8. Ang CW, Tan L, Sykes ML, AbuGharbiyeh N, Debnath A, Reid JC, West NP, Avery VM, Cooper MA, Blaskovich MAT (2020) Antitubercular and antiparasitic 2-nitroimidazopyrazinones with improved potency and solubility. J Med Chem 63:15726–15751. https://doi.org/10.1021/acs.jmedchem.0c01372

    Article  CAS  Google Scholar 

  9. Cheng Y-J, Liu Z-Y, Liang H-J, Fang C-T, Zhang N-N, Zhang T-Y, Yan M (2019) Discovery of (3-Benzyl-5-hydroxyphenyl)carbamates as new antitubercular agents with potent in vitro and in vivo efficacy. Molecules 24:2021. https://doi.org/10.3390/molecules24102021

    Article  CAS  Google Scholar 

  10. Karczmarzyk Z, Swatko-Ossor M, Wysocki W, Drozd M, Ginalska G, Pachuta-Stec A, Pitucha M (2020) New application of 1,2,4-triazole derivatives as antitubercular agents. Structure, in vitro screening and docking studies. Molecules 25:6033. https://doi.org/10.3390/molecules25246033

    Article  CAS  Google Scholar 

  11. Krause M, Foks H, Ziembicka D, Augustynowicz-Kopeć E, Głogowska A, Korona-Głowniak I, Bojanowski K, Siluk D, Gobis K (2020) 4-Substituted picolinohydrazonamides as a new class of potential antitubercular agents. Eur J Med Chem 190:112106. https://doi.org/10.1016/j.ejmech.2020.112106

    Article  CAS  Google Scholar 

  12. Kasetti AB, Singhvi I, Nagasuri R, Bhandare RR, Shaik AB (2021) Thiazole-chalcone hybrids as prospective antitubercular and antiproliferative agents: design, synthesis, biological, molecular docking studies and in silico ADME evaluation. Molecules 26:2847. https://doi.org/10.3390/molecules26102847

    Article  CAS  Google Scholar 

  13. Oh S, Libardo MDJ, Azeeza S, Pauly GT, Roma JSO, Sajid A, Tateishi Y, Duncombe C, Goodwin M, Ioerger TR, Wyatt PG, Ray PC, Gray DW, Boshoff HIM, Barry CE (2021) Structure-Activity Relationships of Pyrazolo[1,5-a]pyrimidin-7(4 H )-ones as Antitubercular Agents. ACS Infect Dis 7:479–492. https://doi.org/10.1021/acsinfecdis.0c00851

    Article  CAS  Google Scholar 

  14. Jiménez-Juárez R, Cruz-Chávez W, de Jesús-Ramírez N, Castro-Ramírez GI, Uribe-González I, Martínez-Mejía G, Ruiz-Nicolás R, Aguirre-Alvarado C, Castrejón-Jiménez NS, García-Pérez BE (2020) Synthesis and antimycobacterial activity of 2,5-disubstituted and 1,2,5-trisubstituted benzimidazoles. Front Chem 8:433. https://doi.org/10.3389/fchem.2020.00433

    Article  CAS  Google Scholar 

  15. Cade CE, Dlouhy AC, Medzihradszky KF, Salas-Castillo SP, Ghiladi RA (2010) Isoniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: Catalase, peroxidase, and INH-NADH adduct formation activities: Isoniazid-Resistance Conferring Mutations in Mtb KatG. Protein Sci 19:458–474. https://doi.org/10.1002/pro.324

    Article  CAS  Google Scholar 

  16. Hsu L-Y, Lai L-Y, Hsieh P-F, Lin T-L, Lin W-H, Tasi H-Y, Lee W-T, Jou R, Wang J-T (2020) Two novel katG Mutations Conferring Isoniazid Resistance in Mycobacterium tuberculosis. Front Microbiol 11:1644. https://doi.org/10.3389/fmicb.2020.01644

    Article  Google Scholar 

  17. Dar AM, Mir S (2017) Molecular docking: approaches, types, applications and basic challenges. J Anal Bioanal Tech. https://doi.org/10.4172/2155-9872.1000356

    Article  Google Scholar 

  18. A.I. (Arthur I. Vogel, Vogel’s textbook of quantitative chemical analysis, Fifth edition / [revised by ... G.H. Jeffery ... [and others]. Harlow, Essex, England : Longman Scientific & Technical ; New York : Wiley, 1989. https://search.library.wisc.edu/catalog/999612906602121.

  19. Finar IL (1975) Organic chemistry. 2: Stereochemistry and the chemistry of natural products, 5th edn. Longmans, London

    Google Scholar 

  20. Sykes P (1970) A guidebook to mechanism in organic chemistry, 3rd edn. Longmans, Harlow

    Google Scholar 

  21. Morrison RT, Boyd RN (1992) Organic chemistry, 6th edn. Prentice Hall, Englewood, Cliffs, N.J.

    Google Scholar 

  22. Vijayakumar S, Manogar P, Prabhu S, Sanjeevkumar Singh RA (2018) Novel ligand-based docking; molecular dynamic simulations; and absorption, distribution, metabolism, and excretion approach to analyzing potential acetylcholinesterase inhibitors for Alzheimer’s disease. J Pharm Anal 8:413–420. https://doi.org/10.1016/j.jpha.2017.07.006

    Article  Google Scholar 

  23. Collins L, Franzblau SG (1997) Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 41:1004–1009

    Article  CAS  Google Scholar 

  24. Roy S, Sharma S, Sharma M, Aggarwal R, Bose M (2004) Induction of nitric oxide release from the human alveolar epithelial cell line A549: an in vitro correlate of innate immune response to Mycobacterium tuberculosis. Immunology 112:471–480. https://doi.org/10.1046/j.1365-2567.2004.01905.x

    Article  CAS  Google Scholar 

  25. Collee JG (1996) Practical medical microbiology, Churchill Livingstone. Edinburgh, New York

    Google Scholar 

  26. Cappuccino JG, Sherman N (1992) Microbiology: a laboratory manual, 3rd edn. Benjamin/Cummings Pub. Co, Redwood City, Calif

    Google Scholar 

  27. Vogel AI, Bassett J (1978) Vogel’s textbook of quantitative inorganic analysis: including elementary instrumental analysis, 4th edn. Longman, London, New York

    Google Scholar 

  28. Krishnan VSH, Chowdary KS, Dubey PK, Vijaya S (2010) ChemInform Abstract: Studies on the Synthesis of 2-Phenylsulfonyl-3-styrylquinoxalines. ChemInform. https://doi.org/10.1002/chin.200140147

    Article  Google Scholar 

  29. Pan P, Tonge PJ (2012) Targeting InhA, the FASII Enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. CTMC 12:672–693. https://doi.org/10.2174/156802612799984535

    Article  CAS  Google Scholar 

  30. He X, Alian A, Ortiz de Montellano PR (2007) Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorganic Med Chem 15:6649–6658. https://doi.org/10.1016/j.bmc.2007.08.013

    Article  CAS  Google Scholar 

  31. Xia Y, Zhou Y, Carter DS, McNeil MB, Choi W, Halladay J, Berry PW, Mao W, Hernandez V, O’Malley T, Korkegian A, Sunde B, Flint L, Woolhiser LK, Scherman MS, Gruppo V, Hastings C, Robertson GT, Ioerger TR, Sacchettini J, Tonge PJ, Lenaerts AJ, Parish T, Alley M (2018) Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA. Life Sci. Alliance 1:e201800025. https://doi.org/10.26508/lsa.201800025

    Article  Google Scholar 

  32. Desai N, Bhavsar A, Baldaniya B (2009) Synthesis and antimicrobial activity of 5-imidazolinone derivatives. Indian J Pharm Sci 71:90. https://doi.org/10.4103/0250-474X.51953

    Article  CAS  Google Scholar 

  33. Ahluwalia VK, Tyagi R, Khurana A (2010) ChemInform Abstract: synthesis of 3-(Thiadiazol-2-ylthio-, Pyridin-2-ylthio- and Benzimidazol-2-ylthio)-2H-1-benzopyran-2-ones. ChemInform. https://doi.org/10.1002/chin.199122145

    Article  Google Scholar 

  34. Chauhan PM, Sunduru N, Sharma M (2010) Recent advances in the design and synthesis of heterocycles as anti-tubercular agents. Future Med Chem 2:1469–1500. https://doi.org/10.4155/fmc.10.227

    Article  CAS  Google Scholar 

  35. Nguyen Tien C, Tran Thi Cam D, Bui Manh H, Nguyen Dang D (2016) Synthesis and antibacterial activity of some derivatives of 2-methylbenzimidazole containing 1,3,4-oxadiazole or 1,2,4-triazole heterocycle. J Chem. https://doi.org/10.1155/2016/1507049

    Article  Google Scholar 

  36. Hameed P S, Raichurkar A, Madhavapeddi P, Menasinakai S, Sharma S, Kaur P, Nandishaiah R, Panduga V, Reddy J, Sambandamurthy VK, Sriram D (2014) Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing. ACS Med Chem Lett 5:820–825. https://doi.org/10.1021/ml5001728

    Article  CAS  Google Scholar 

  37. Kumar K, Awasthi D, Lee S-Y, Zanardi I, Ruzsicska B, Knudson S, Tonge PJ, Slayden RA, Ojima I (2011) Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents. J Med Chem 54:374–381. https://doi.org/10.1021/jm1012006

    Article  CAS  Google Scholar 

  38. Marrakchi H, Lanéelle G, Quémard A (2000) InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiology 146:289–296. https://doi.org/10.1099/00221287-146-2-289

    Article  CAS  Google Scholar 

  39. Mehboob S, Hevener KE, Truong K, Boci T, Santarsiero BD, Johnson ME (2012) Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis Enoyl Reductase (FabI) inhibitors. J Med Chem 55:5933–5941. https://doi.org/10.1021/jm300489v

    Article  CAS  Google Scholar 

  40. Venugopala KN, Chandrashekharappa S, Deb PK, Tratrat C, Pillay M, Chopra D, Al-Shar’i NA, Hourani W, Dahabiyeh LA, Borah P, Nagdeve RD, Nayak SK, Padmashali B, Morsy MA, Aldhubiab BE, Attimarad M, Nair AB, Sreeharsha N, Haroun M, Shashikanth S, Mohanlall V, Mailavaram R (2021) Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme. J Enzyme Inhib Med Chem 36:1471–1486. https://doi.org/10.1080/14756366.2021.1919889

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Mr. Ranadip Dutta, Department of English, Arunachal University of Studies, Namsai, for syntax and grammar correction.

Funding

Not applicable.

Author information

Author notes

  1. Ravi Kumar Rajan

    Present address: Department of Pharmacology, Girijananda Chowdhury Institute of Pharmaceutical Science, Tezpur, India

Authors and Affiliations

  1. Department of Pharmaceutical Chemistry, PSG College of Pharmacy, The Tamil Nadu Dr. M.G.R. Medical University, Chennai, India

    Umaa Kuppuswamy & Arvinth Kumar

  2. Department of Pharmacology, PSG College of Pharmacy, The Tamil Nadu Dr. M.G.R. Medical University, Chennai, India

    Ravi Kumar Rajan & Muthiah Ramanathan

Authors
  1. Umaa Kuppuswamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ravi Kumar Rajan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arvinth Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Muthiah Ramanathan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RKR and AK performed the computational simulations and RKR analyzed the data. UK has conducted all the chemistry and biology-related experiments and UK, RKR and MR have analyzed the data. RKR and UK prepared the manuscript, and RM has revised the manuscript. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Umaa Kuppuswamy.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent of publication

Not applicable.

Competing interest

The authors have no competing interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1

. Spectral data of lead compounds.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kuppuswamy, U., Rajan, R.K., Kumar, A. et al. In-silico and in-vitro analysis of novel substituted benzimidazolyl derivatives for antimycobacterial potentials targeting enoyl acyl carrier protein reductase (InhA). Futur J Pharm Sci 8, 61 (2022). https://doi.org/10.1186/s43094-022-00449-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s43094-022-00449-x

Keywords